Shiraz Institute for Cancer Research | Research $ Development
Researchers Students patients
فا

      Research and Development laboratory 

 

  Research and Development (R&D) laboratory started in 2013 with the aim to establish a centralized foundation to coordinate research activities and production in the field of biosimilar biopharmaceuticals, monoclonal antibodies, recombinant and fusion proteins (in Eukaryotic and Prokaryotic expression hosts) and ex-vivo cell therapy and to step in an expanded scientific and industrial motivation.

To date R&D laboratory has produced several mAbs that are mainly used in the field of cancer diagnosis (anti-CD3, anti-CD8 and …) and cancer therapy (Pertuzumab and Aflibercept) as well as recombinant proteins (IL-2 and GCSF). R&D laboratory is also involved in educational activities like training researchers and most importantly training of MSc and PhD students in their thesis work.

Vision & Mission

 

Vision

A society where scientific innovations made possible through biotechnology conquer disease and advance healthfulness.

 

Mission

Act as a base to expand basic and applied researches in the areas related to biosimilar biopharmaceuticals and monoclonal/polyclonal antibodies

Create a strong infrastructure for R&D and commercialization

Improve cancer cell-based treatment in the country (like CAR T-Cell therapy)

Fostering collaboration with industry, both locally and globally.

Current projects

1.    Production and characterization of biosimilar version of Aflibercept

2.    Production and characterization of cell internalization activities of Tatibody (recombinant Pertuzumab containing the cell penetrating peptide from Tat protein)

3.    Cloning, expression and characterization of an in silico designed variant of interleukin 4, to facilitate its purification using cyanogen bromide

4.    Production of human recombinant IL-2 and evaluation of its therapeutic effect in combination with Pertuzumab on an ErbB2 positive breast cancer cell line

5.    Production of a Fc-fused anti-PD-1 scFv and a Fc-fused CD80 for dual blockade of PD-1 and CTLA-4 in cancer immunotherapy.

6.    Real-Time PCR data normalization software design

7.    In silico identification of a cancer associated biomarker and validation in breast cancer patients using Real-Time PCR technique

8.    Designing and evaluating 3rd generation CAR T-meso to induce immune response against pancreatic cancer cell lines

9. Semi-industrial production of IL-2 

Recent Publication

 

  1. Rezaei Z, Reet N.V, Pouladfar G, Kühne V, Ramezani A, Sarkari B, Pourabbas B and Büscher P. Expression of a rK39 homologue from an Iranian Leishmania infantum isolate in Leishmania tarentolae for serodiagnosis of visceral leishmaniasis. Parasites & Vectors. 2019 12:593. doi.org/10.1186/s13071-019-3839-3  
  2. Asgari A, Sharifzadeh S, Ghaderi A, Hosseini A, and Ramezani A*. In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells. Mol Biol Rep. 2019 46(6):6205-6213. doi.org/10.1007/s11033-019-05059-0
  3. Toghraie FS, Ghaderi A, and Ramezani A*. Homology Modeling of an Alternative Splice Variant of Human Granulocyte Colony-Stimulating Factor, G-CSF Isoform D, and Study of Its Binding Properties by Molecular Docking. Int J Pept Res Ther (2019) doi:10.1007/s10989-019-09814-6.
  4. Toghraie FS, Yazdanpanah-Samani M, Mahmoudi Maymand E, Hosseini A, Asgari A, Ramezani A, Ghaderi A. Molecular Cloning, Expression and Purification of G-CSF Isoform D, an Alternative Splice Variant of Human G-CSF. Iranian journal of allergy, asthma, and immunology. 2019;18(4):419-26.
  5. Yousefinejad F, Jowkar F, Barani S, Jamali E, Mahmoudi E, Ramezani A, et al. Killer cell immunoglobulin-like receptors (KIRs) genotype and haplotype analysis in Iranians with non-melanoma Skin Cancers. Iranian Biomedical Journal. 2019;23(5):330-7.
  6. Hashemi SMA, Sarvari J, Fattahi MR, Dowran R, Ramezani A, Hosseini SY. Comparison of ISG15, IL28B and USP18 mRNA levels in peripheral blood mononuclear cells of chronic hepatitis B virus infected patients and healthy individuals. Gastroenterology and Hepatology from Bed to Bench. 2019;12(1):38-45.
  7. Ghaderi F, Ahmadvand S, Ramezani A, Montazer M, and Ghaderi A,. Production and characterization of monoclonal antibody against a triple negative breast cancer cell line. Biochemical and biophysical research communications 2018; 505 (1), 181-186.
  8. Zargar P, Ghani E, Mashayekhi FJ, Ramezani A, Eftekhar E. Acriflavine enhances the antitumor activity of the chemotherapeutic drug 5‑fluorouracil in colorectal cancer cells. Oncology letters. 2018;15(6):10084-90.
  9. Shaaban Z, Shirazi MRJ, Nooranizadeh MH, Tamadon A, Rahmanifar F, Ahmadloo S, Ramezani A, et al. Decreased expression of arginine-phenylalanine-amide-related peptide-3 gene in dorsomedial hypothalamic nucleus of constant light exposure model of polycystic ovarian syndrome. International journal of fertility & sterility. 2018;12(1):43.
  10. Ramezani A, Ghaderi A. Using a Dihydrofolate Reductase-Based Strategy for Producing the Biosimilar Version of Pertuzumab in CHO-S Cells. Monoclonal antibodies in immunodiagnosis and immunotherapy. 2018;37(1):26-37.
  11. Khajeh S, Razban V, Talaei-Khozani T, Soleimani M, Asadi-Golshan R, Dehghani F, Ramezani A, et al. Enhanced chondrogenic differentiation of dental pulp-derived mesenchymal stem cells in 3D pellet culture system: effect of mimicking hypoxia. Biologia. 2018;73(7):715-26.
  12. Kavousipour S, Mokarram P, Gargari S, Mostafavi-Pour Z, Barazesh M, Ramezani A, et al. A Comparison between Cell, Protein and Peptide-Based Approaches for Selection of Nanobodies against CD44 from a Synthetic Library. Protein and peptide letters. 2018;25(6):580-8.
  13. Toghraie FS, Sharifzadeh SM, Ramezani A, Maymand EM, Yazdanpanah-Samani M, Ghaderi A. Cloning and Expression of Recombinant Human Interleukin-7 in Chinese Hamster Ovary (CHO) Cells. Reports of biochemistry & molecular biology. 2017;6(1):66.
  14. Rashidi M, Seghatoleslam A, Namavari M, Amiri A, Fahmidehkar MA, Ramezani A, et al. Selective Cytotoxicity and apoptosis-induction of Cyrtopodion scabrum extract against digestive cancer cell lines. Int J Cancer Mana. 2017.
  15. Ramezani A, Maymand EM, Yazdanpanah-Samani M, Hosseini A, Toghraie FS, Ghaderi A. Improving Pertuzumab production by gene optimization and proper signal peptide selection. Protein expression and purification. 2017;135:24-32.